- Home
- YHGJ vs LSB Comparison
YHGJ vs LSB Comparison
Compare YHGJ & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- LSB
- Stock Information
- Founded
- YHGJ 1975
- LSB 2002
- Country
- YHGJ United States
- LSB China
- Employees
- YHGJ N/A
- LSB N/A
- Industry
- YHGJ Specialty Chemicals
- LSB
- Sector
- YHGJ Industrials
- LSB
- Exchange
- YHGJ Nasdaq
- LSB NYSE
- Market Cap
- YHGJ 22.5M
- LSB 22.3M
- IPO Year
- YHGJ 1997
- LSB N/A
- Fundamental
- Price
- YHGJ $0.78
- LSB $0.98
- Analyst Decision
- YHGJ
- LSB
- Analyst Count
- YHGJ 0
- LSB 0
- Target Price
- YHGJ N/A
- LSB N/A
- AVG Volume (30 Days)
- YHGJ 25.8K
- LSB 13.8K
- Earning Date
- YHGJ 05-20-2025
- LSB 06-21-2025
- Dividend Yield
- YHGJ N/A
- LSB N/A
- EPS Growth
- YHGJ N/A
- LSB N/A
- EPS
- YHGJ N/A
- LSB N/A
- Revenue
- YHGJ $17,861,000.00
- LSB $79,415,311.00
- Revenue This Year
- YHGJ N/A
- LSB $39.33
- Revenue Next Year
- YHGJ N/A
- LSB $75.61
- P/E Ratio
- YHGJ N/A
- LSB N/A
- Revenue Growth
- YHGJ 1.21
- LSB N/A
- 52 Week Low
- YHGJ $0.43
- LSB $0.36
- 52 Week High
- YHGJ $1.66
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- YHGJ 45.83
- LSB 27.77
- Support Level
- YHGJ $0.71
- LSB $0.91
- Resistance Level
- YHGJ $0.98
- LSB $1.09
- Average True Range (ATR)
- YHGJ 0.07
- LSB 0.06
- MACD
- YHGJ -0.00
- LSB 0.01
- Stochastic Oscillator
- YHGJ 49.86
- LSB 16.13
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.